Skip to main content
Top
Published in: Infectious Diseases and Therapy 2/2019

Open Access 01-06-2019 | Cephalosporin Antibiotic | Original Research

The Clinical and Molecular Epidemiology of CTX-M-9 Group Producing Enterobacteriaceae Infections in Children

Authors: Latania K. Logan, Rachel L. Medernach, T. Nicholas Domitrovic, Jared R. Rispens, Andrea M. Hujer, Nadia K. Qureshi, Steven H. Marshall, David C. Nguyen, Susan D. Rudin, Xiaotian Zheng, Sreenivas Konda, Robert A. Weinstein, Robert A. Bonomo

Published in: Infectious Diseases and Therapy | Issue 2/2019

Login to get access

Abstract

Introduction

The pandemic of extended-spectrum beta-lactamase-(ESBL)-producing Enterobacteriaceae (Ent) is strongly linked to the dissemination of CTX-M-type-ESBL-Ent. We sought to define the epidemiology of infections in children due to an emerging resistance type, CTX-M-9-group-producing-Ent (CTX-M-9-grp-Ent).

Methods

A retrospective matched case-control analysis of children with CTX-M-9-grp-Ent infections who received medical care at three Chicago area hospitals was performed. Cases were defined as children possessing extended-spectrum cephalosporin-resistant (ESC-R) infections due to blaCTX-M-9. PCR and DNA analysis assessed beta-lactamase (bla) genes, multi-locus sequence types (MLST) and phylogenetic grouping of E. coli. Controls were children with ESC-susceptible (ESC-S)-Ent infections matched one case to three controls by age, source, and hospital. The clinical-epidemiologic predictors of CTX-M-9-grp-Ent infection were assessed.

Results

Of 356 ESC-R-Ent isolates from children (median age 4.1 years), the CTX-M-9-group was the solely detected bla gene in 44 (12.4%). The predominant species was E. coli (91%) of virulent phylogroups D (60%) and B2 (40%). MLST revealed multiple strain types. On multivariable analysis, CTX-M-9-grp-Ent occurred more often in E. coli than other Ent genera (OR 7.4, 95% CI 2.4, 27.2), children of non-Black-White-Hispanic race (OR 7.4, 95% CI 2.4, 28.2), and outpatients (OR 4.5, 95% CI 1.7, 12.3), which was a very unexpected finding for infections due to antibiotic-resistant bacteria. Residents of South Chicago had a 6.7 times higher odds of having CTX-M-9-grp-Ent infections than those in the reference region (West), while residence in Northwestern Chicago was associated with an 81% decreased odds of infection. Other demographic, comorbidity, invasive-device, and antibiotic use differences were not found.

Conclusion

CTX-M-9-grp-Ent infection may be associated with patient residence and is occurring in children without traditional in-patient exposure risk factors. This suggests that among children, the community environment may be a key contributor in the spread of these resistant pathogens.
Literature
1.
go back to reference Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–36.CrossRef Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–36.CrossRef
2.
go back to reference Medernach RL, Logan LK. The growing threat of antibiotic resistance in children. Infect Dis Clin N Am. 2018;32(1):1–17.CrossRef Medernach RL, Logan LK. The growing threat of antibiotic resistance in children. Infect Dis Clin N Am. 2018;32(1):1–17.CrossRef
3.
go back to reference Lukac PJ, Bonomo RA, Logan LK. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat. Clin Infect Dis. 2015;60(9):1389–97.PubMedPubMedCentral Lukac PJ, Bonomo RA, Logan LK. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat. Clin Infect Dis. 2015;60(9):1389–97.PubMedPubMedCentral
4.
go back to reference Logan LK, Renschler JP, Gandra S, Weinstein RA, Laxminarayan R, Centers for Disease Control, et al. Carbapenem-resistant Enterobacteriaceae in children, United States, 1999–2012. Emerg Infect Dis. 2015;21(11):2014–21.CrossRef Logan LK, Renschler JP, Gandra S, Weinstein RA, Laxminarayan R, Centers for Disease Control, et al. Carbapenem-resistant Enterobacteriaceae in children, United States, 1999–2012. Emerg Infect Dis. 2015;21(11):2014–21.CrossRef
5.
go back to reference Logan LK, Braykov NP, Weinstein RA, Laxminarayan R, CDC Epicenters Prevention Program. Extended-spectrum beta-lactamase-producing and third-generation cephalosporin-resistant enterobacteriaceae in children: trends in the United States, 1999–2011. J Pediatr Infect Dis Soc. 2014;3(4):320–8.CrossRef Logan LK, Braykov NP, Weinstein RA, Laxminarayan R, CDC Epicenters Prevention Program. Extended-spectrum beta-lactamase-producing and third-generation cephalosporin-resistant enterobacteriaceae in children: trends in the United States, 1999–2011. J Pediatr Infect Dis Soc. 2014;3(4):320–8.CrossRef
6.
go back to reference Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–96.CrossRef Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–96.CrossRef
7.
go back to reference Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, et al. The epidemic of extended-spectrum-beta-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. MBio. 2013;4(6):e00377-13.CrossRef Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, et al. The epidemic of extended-spectrum-beta-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. MBio. 2013;4(6):e00377-13.CrossRef
8.
go back to reference Miles-Jay A, Weissman SJ, Adler AL, Tchesnokova V, Sokurenko EV, Baseman JG, et al. Epidemiology and antimicrobial resistance characteristics of the sequence type 131-H30 subclone among extraintestinal Escherichia coli collected from US children. Clin Infect Dis. 2017;66(3):411–9.CrossRef Miles-Jay A, Weissman SJ, Adler AL, Tchesnokova V, Sokurenko EV, Baseman JG, et al. Epidemiology and antimicrobial resistance characteristics of the sequence type 131-H30 subclone among extraintestinal Escherichia coli collected from US children. Clin Infect Dis. 2017;66(3):411–9.CrossRef
9.
go back to reference Cantón R, González-Alba JM, Galán JC. CTX-M enzymes: origin and diffusion. Front Microbiol. 2012;3:110.CrossRef Cantón R, González-Alba JM, Galán JC. CTX-M enzymes: origin and diffusion. Front Microbiol. 2012;3:110.CrossRef
10.
go back to reference Merida-Vieyra J, De Colsa A, Castañeda YC, Barbosa PA, Andrade AA. First report of group CTX-M-9 extended spectrum beta-lactamases in Escherichia coli isolates from pediatric patients in Mexico. PLoS One. 2016;11(12):e0168608.CrossRef Merida-Vieyra J, De Colsa A, Castañeda YC, Barbosa PA, Andrade AA. First report of group CTX-M-9 extended spectrum beta-lactamases in Escherichia coli isolates from pediatric patients in Mexico. PLoS One. 2016;11(12):e0168608.CrossRef
11.
go back to reference Castanheira M, Mendes RE, Jones RN, Sader HS. Changes in the frequencies of beta-lactamase genes among Enterobacteriaceae isolates in US hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against beta-lactamase-producing isolates. Antimicrob Agents Chemother. 2016;60(8):4770–7.CrossRef Castanheira M, Mendes RE, Jones RN, Sader HS. Changes in the frequencies of beta-lactamase genes among Enterobacteriaceae isolates in US hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against beta-lactamase-producing isolates. Antimicrob Agents Chemother. 2016;60(8):4770–7.CrossRef
12.
go back to reference Oteo J, Diestra K, Juan C, Bautista V, Novais Â, Pérez-Vázquez M, et al. Extended-spectrum β-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Int J Antimicrob Agents. 2009;34(2):173–6.CrossRef Oteo J, Diestra K, Juan C, Bautista V, Novais Â, Pérez-Vázquez M, et al. Extended-spectrum β-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Int J Antimicrob Agents. 2009;34(2):173–6.CrossRef
13.
go back to reference Logan LK, Hujer AM, Marshall SH, Domitrovic TN, Rudin SD, Zheng X, et al. Analysis of beta-lactamase resistance determinants in enterobacteriaceae from Chicago children: a multicenter survey. Antimicrob Agents Chemother. 2016;60(6):3462–9.CrossRef Logan LK, Hujer AM, Marshall SH, Domitrovic TN, Rudin SD, Zheng X, et al. Analysis of beta-lactamase resistance determinants in enterobacteriaceae from Chicago children: a multicenter survey. Antimicrob Agents Chemother. 2016;60(6):3462–9.CrossRef
14.
go back to reference Logan LK, Nguyen DC, Scaggs-Huang FA, Qureshi NK, Charnot-Katsikas A, Bartlett AH, et al. A multi-centered case–case–control study of factors associated with Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae (KPC-CRE) infections in children and young adults. Pediatr Infect Dis J. 2019;38(6):HS2–5 (E-pub ahead of print). Logan LK, Nguyen DC, Scaggs-Huang FA, Qureshi NK, Charnot-Katsikas A, Bartlett AH, et al. A multi-centered case–case–control study of factors associated with Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae (KPC-CRE) infections in children and young adults. Pediatr Infect Dis J. 2019;38(6):HS2–5 (E-pub ahead of print).
15.
go back to reference Logan LK, Medernach RL, Rispens JR, Marshall SH, Hujer AM, Domitrovic TN, et al. Community origins and regional differences highlight risk of plasmid-mediated fluoroquinolone resistant Enterobacteriaceae infections in children. Pediatr Infect Dis J 2019;38(7) (E-pub ahead of print). Logan LK, Medernach RL, Rispens JR, Marshall SH, Hujer AM, Domitrovic TN, et al. Community origins and regional differences highlight risk of plasmid-mediated fluoroquinolone resistant Enterobacteriaceae infections in children. Pediatr Infect Dis J 2019;38(7) (E-pub ahead of print).
17.
go back to reference Powell EA, Haslam D, Mortensen JE. Performance of the check-points check-MDR CT103XL assay utilizing the CDC/FDA antimicrobial resistance isolate bank. Diagn Microbiol Infect Dis. 2017;88(3):219–21.CrossRef Powell EA, Haslam D, Mortensen JE. Performance of the check-points check-MDR CT103XL assay utilizing the CDC/FDA antimicrobial resistance isolate bank. Diagn Microbiol Infect Dis. 2017;88(3):219–21.CrossRef
18.
go back to reference Bingen-Bidois M, Clermont O, Bonacorsi S, Terki M, Brahimi N, Loukil C, et al. Phylogenetic analysis and prevalence of urosepsis strains of Escherichia coli bearing pathogenicity island-like domains. Infect Immun. 2002;70(6):3216–26.CrossRef Bingen-Bidois M, Clermont O, Bonacorsi S, Terki M, Brahimi N, Loukil C, et al. Phylogenetic analysis and prevalence of urosepsis strains of Escherichia coli bearing pathogenicity island-like domains. Infect Immun. 2002;70(6):3216–26.CrossRef
19.
go back to reference Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005;43(8):4178–82.CrossRef Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005;43(8):4178–82.CrossRef
20.
go back to reference Jaureguy F, Landraud L, Passet V, Diancourt L, Frapy E, Guigon G, et al. Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BMC Genom. 2008;9:560-2164-9-560.CrossRef Jaureguy F, Landraud L, Passet V, Diancourt L, Frapy E, Guigon G, et al. Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BMC Genom. 2008;9:560-2164-9-560.CrossRef
21.
go back to reference Logan LK, Meltzer LA, McAuley JB, Hayden MK, Beck T, Braykov NP, et al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in children: a two-center case-case-control study of risk factors and outcomes in Chicago, Illinois. J Pediatr Infect Dis Soc. 2014;3(4):312–9.CrossRef Logan LK, Meltzer LA, McAuley JB, Hayden MK, Beck T, Braykov NP, et al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in children: a two-center case-case-control study of risk factors and outcomes in Chicago, Illinois. J Pediatr Infect Dis Soc. 2014;3(4):312–9.CrossRef
23.
go back to reference Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 2005;63(3):219–28.CrossRef Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 2005;63(3):219–28.CrossRef
24.
go back to reference Zerr DM, Qin X, Oron AP, Adler AL, Wolter DJ, Berry JE, et al. Pediatric infection and intestinal carriage due to extended-spectrum-cephalosporin-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014;58(7):3997–4004.CrossRef Zerr DM, Qin X, Oron AP, Adler AL, Wolter DJ, Berry JE, et al. Pediatric infection and intestinal carriage due to extended-spectrum-cephalosporin-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014;58(7):3997–4004.CrossRef
25.
go back to reference Harris PN, Tambyah PA, Lye DC, Mo Y, Lee TH, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;13(10):984–94.CrossRef Harris PN, Tambyah PA, Lye DC, Mo Y, Lee TH, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;13(10):984–94.CrossRef
26.
go back to reference Beetz R, Westenfelder M. Antimicrobial therapy of urinary tract infections in children. Int J Antimicrob Agents. 2011;38:42–50.CrossRef Beetz R, Westenfelder M. Antimicrobial therapy of urinary tract infections in children. Int J Antimicrob Agents. 2011;38:42–50.CrossRef
27.
go back to reference Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14.CrossRef Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14.CrossRef
29.
go back to reference Kuenzli E, Jaeger VK, Frei R, Neumayr A, DeCrom S, Haller S, et al. High colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia—a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. BMC Infect Dis. 2014;14(1):528.CrossRef Kuenzli E, Jaeger VK, Frei R, Neumayr A, DeCrom S, Haller S, et al. High colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia—a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. BMC Infect Dis. 2014;14(1):528.CrossRef
30.
go back to reference Haverkate MR, Platteel TN, Fluit A, Stuart JC, Leverstein-van Hall M, Thijsen S, et al. Quantifying within-household transmission of extended-spectrum β-lactamase-producing bacteria. Clin Microbiol Infect. 2017;23(1):46.e1–7.CrossRef Haverkate MR, Platteel TN, Fluit A, Stuart JC, Leverstein-van Hall M, Thijsen S, et al. Quantifying within-household transmission of extended-spectrum β-lactamase-producing bacteria. Clin Microbiol Infect. 2017;23(1):46.e1–7.CrossRef
31.
go back to reference Silbergeld EK, Graham J, Price LB. Industrial food animal production, antimicrobial resistance, and human health. Annu Rev Public Health. 2008;29:151–69.CrossRef Silbergeld EK, Graham J, Price LB. Industrial food animal production, antimicrobial resistance, and human health. Annu Rev Public Health. 2008;29:151–69.CrossRef
32.
go back to reference Grasselli E, François P, Gutacker M, Gettler B, Benagli C, Convert M, et al. Evidence of horizontal gene transfer between human and animal commensal Escherichia coli strains identified by microarray. FEMS Immunol Med Microbiol. 2008;53(3):351–8.CrossRef Grasselli E, François P, Gutacker M, Gettler B, Benagli C, Convert M, et al. Evidence of horizontal gene transfer between human and animal commensal Escherichia coli strains identified by microarray. FEMS Immunol Med Microbiol. 2008;53(3):351–8.CrossRef
33.
go back to reference Zerr DM, Weissman SJ, Zhou C, Kronman MP, Adler AL, Berry JE, et al. The molecular and clinical epidemiology of extended-spectrum cephalosporin–and carbapenem-resistant Enterobacteriaceae at 4 US pediatric hospitals. J Pediatr Infect Dis Soc. 2017;6:366–75.CrossRef Zerr DM, Weissman SJ, Zhou C, Kronman MP, Adler AL, Berry JE, et al. The molecular and clinical epidemiology of extended-spectrum cephalosporin–and carbapenem-resistant Enterobacteriaceae at 4 US pediatric hospitals. J Pediatr Infect Dis Soc. 2017;6:366–75.CrossRef
34.
go back to reference Meropol SB, Haupt AA, Debanne SM. Incidence and outcomes of infections caused by multidrug-resistant enterobacteriaceae in children, 2007–2015. J Pediatr Infect Dis Soc. 2017;7(1):36–45.CrossRef Meropol SB, Haupt AA, Debanne SM. Incidence and outcomes of infections caused by multidrug-resistant enterobacteriaceae in children, 2007–2015. J Pediatr Infect Dis Soc. 2017;7(1):36–45.CrossRef
Metadata
Title
The Clinical and Molecular Epidemiology of CTX-M-9 Group Producing Enterobacteriaceae Infections in Children
Authors
Latania K. Logan
Rachel L. Medernach
T. Nicholas Domitrovic
Jared R. Rispens
Andrea M. Hujer
Nadia K. Qureshi
Steven H. Marshall
David C. Nguyen
Susan D. Rudin
Xiaotian Zheng
Sreenivas Konda
Robert A. Weinstein
Robert A. Bonomo
Publication date
01-06-2019
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 2/2019
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-019-0237-2

Other articles of this Issue 2/2019

Infectious Diseases and Therapy 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.